Last10K.com

Ampio Pharmaceuticals, Inc. (AMPE) SEC Filing 10-K Annual report for the fiscal year ending Saturday, December 31, 2016

Ampio Pharmaceuticals, Inc.

CIK: 1411906 Ticker: AMPE
Document And Entity Information - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2016
Mar. 01, 2017
Jun. 30, 2016
Document Information [Line Items]   
Document Type10-K  
Amendment Flagfalse  
Document Period End DateDec. 31, 2016  
Document Fiscal Year Focus2016  
Document Fiscal Period FocusFY  
Entity Registrant NameAmpio Pharmaceuticals, Inc.  
Entity Central Index Key0001411906  
Current Fiscal Year End Date--12-31  
Entity Well-known Seasoned IssuerNo  
Entity Voluntary FilersNo  
Entity Current Reporting StatusYes  
Entity Filer CategoryAccelerated Filer  
Entity Public Float  $ 64.4
Trading SymbolAMPE  
Entity Common Stock, Shares Outstanding 57,242,164 

View differences made from one year to another to evaluate Ampio Pharmaceuticals, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Ampio Pharmaceuticals, Inc..

Continue

Assess how Ampio Pharmaceuticals, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Ampio Pharmaceuticals, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2017 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Rating

Learn More
Bullish Bearish Neutral
Filter Sentiment:
All
Positive
Negative
Filter Category:
All
Financial
Revenue
Other
Filter Subcategory:
All
Expense
Shares
Product
Other
Inside Ampio Pharmaceuticals, Inc.'s 10-K Annual Report:

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Document And Entity Information
Balance Sheets
Balance Sheets (parenthetical)
Statements Of Cash Flows
Statements Of Operations
Statements Of Stockholders??? Equity
Basis Of Presentation
Basis Of Presentation - Additional Information (detail)
Commitments And Contingencies
Commitments And Contingencies (tables)
Commitments And Contingencies - Additional Information (detail)
Commitments And Contingencies - Rent Expense (detail)
Commitments And Contingencies - Summary Of Commitments And Contingencies (detail)
Common Stock
Common Stock (tables)
Common Stock - Additional Information (detail)
Common Stock - Sales (detail)
Employee Benefit Plan
Equity Instruments
Equity Instruments (tables)
Equity Instruments - Additional Information (detail)
Equity Instruments - Assumptions Used In Computing Fair Value Of All Options Granted (detail)
Equity Instruments - Stock Option Activity (detail)
Equity Instruments - Summary Of Stock Options Outstanding And Exercisable (detail)
Equity Instruments - Summary Of Stock-based Compensation Expense (detail)
Equity Instruments - Warrants Issued In Conjunction With Its Senior Convertible Debentures (detail)
Equity Instruments - Weighted Average Fair Value Per Share Granted (detail)
Fair Value Considerations
Fair Value Considerations (tables)
Fair Value Considerations - Additional Information (detail)
Fair Value Considerations - Aytu???s Closing Stock Price (detail)
Fair Value Considerations - Financial Assets And Liabilities (detail)
Fair Value Considerations - Sets Forth A Reconciliation Of Changes (detail)
Going Concern
Going Concern (details Textual)
Income Taxes
Income Taxes (tables)
Income Taxes - Additional Information (detail)
Income Taxes - Deferred Tax Assets And Liabilities (detail)
Income Taxes - Reconciliation Of Effective Tax Rate (detail)
Investment In Aytu Bioscience, Inc - Additional Information (detail)
Litigation
Litigation - Additional Information (detail)
Related Party Transactions
Related Party Transactions - Additional Information (detail)
Selected Quarterly Data (unaudited)
Selected Quarterly Data (unaudited) (detail)
Selected Quarterly Data (unaudited) (tables)
Subsequent Events
Subsequent Events - Additional Information (detail)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (policies)
Summary Of Significant Accounting Policies (tables)
Summary Of Significant Accounting Policies - Additional Information (detail)
Summary Of Significant Accounting Policies - Depreciation Expenses (detail)
Summary Of Significant Accounting Policies - Research And Development Costs (detail)
Summary Of Significant Accounting Policies - Schedule Of Fixed Assets (detail)
Trading Security Aytu Bioscience, Inc.

Material Contracts, Statements, Certifications & more

Ampio Pharmaceuticals, Inc. provided additional information to their SEC Filing as exhibits

Ticker: AMPE
CIK: 1411906
Form Type: 10-K Annual Report
Accession Number: 0001144204-17-015100
Submitted to the SEC: Thu Mar 16 2017 4:20:54 PM EST
Accepted by the SEC: Thu Mar 16 2017
Period: Saturday, December 31, 2016
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/ampe/0001144204-17-015100.htm